Pharmchem Stock Performance
| PCHM Stock | USD 3.05 0.00 0.00% |
The company holds a Beta of 0.8, which implies possible diversification benefits within a given portfolio. As returns on the market increase, PharmChem's returns are expected to increase less than the market. However, during the bear market, the loss of holding PharmChem is expected to be smaller as well. At this point, PharmChem has a negative expected return of -0.23%. Please make sure to check PharmChem's variance, as well as the relationship between the value at risk and rate of daily change , to decide if PharmChem performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PharmChem has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 4.2 M |
PharmChem |
PharmChem Relative Risk vs. Return Landscape
If you would invest 362.00 in PharmChem on September 18, 2024 and sell it today you would lose (57.00) from holding PharmChem or give up 15.75% of portfolio value over 90 days. PharmChem is currently does not generate positive expected returns and assumes 3.0225% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of pink sheets are less volatile than PharmChem, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PharmChem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PharmChem's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as PharmChem, and traders can use it to determine the average amount a PharmChem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.076
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PCHM |
Estimated Market Risk
| 3.02 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PharmChem is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PharmChem by adding PharmChem to a well-diversified portfolio.
PharmChem Fundamentals Growth
PharmChem Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of PharmChem, and PharmChem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PharmChem Pink Sheet performance.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.0537 | |||
| Profit Margin | (0.08) % | |||
| Operating Margin | (0.06) % | |||
| Current Valuation | 17.56 K | |||
| Price To Earning | (2.30) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0006 X | |||
| Revenue | 26.45 M | |||
| Cash And Equivalents | 626 K | |||
| Cash Per Share | 0.11 X | |||
| Debt To Equity | 0.37 % | |||
| Book Value Per Share | 1.30 X | |||
| Earnings Per Share | (0.35) X | |||
| Total Asset | 16.66 M | |||
| Retained Earnings | (10.28 M) | |||
| Current Asset | 6.8 M | |||
| Current Liabilities | 5.52 M | |||
About PharmChem Performance
By examining PharmChem's fundamental ratios, stakeholders can obtain critical insights into PharmChem's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that PharmChem is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
PharmChem, Inc. provides PharmChek Sweat Patch that is used to detect drugs of abuse. Its PharmChek Sweat Patch uses sweat as the source and offers alternative to urine testing for cocaine, opiates, amphetamines, PCP, and marijuana. Pharmchem is traded on OTC Exchange in the United States.Things to note about PharmChem performance evaluation
Checking the ongoing alerts about PharmChem for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for PharmChem help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PharmChem generated a negative expected return over the last 90 days | |
| PharmChem has high historical volatility and very poor performance | |
| The company has a current ratio of 0.68, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist PharmChem until it has trouble settling it off, either with new capital or with free cash flow. So, PharmChem's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PharmChem sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PharmChem to invest in growth at high rates of return. When we think about PharmChem's use of debt, we should always consider it together with cash and equity. | |
| PharmChem reported the previous year's revenue of 26.45 M. Net Loss for the year was (2.15 M) with profit before overhead, payroll, taxes, and interest of 5.86 M. |
- Analyzing PharmChem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PharmChem's stock is overvalued or undervalued compared to its peers.
- Examining PharmChem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PharmChem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PharmChem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PharmChem's pink sheet. These opinions can provide insight into PharmChem's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in PharmChem Pink Sheet
PharmChem financial ratios help investors to determine whether PharmChem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PharmChem with respect to the benefits of owning PharmChem security.